Philippe Rougier

Summary

Country: France

Publications

  1. ncbi request reprint Colon cancer
    Philippe Rougier
    Service d Hepato Gastroenterologie, Hopital Ambroise Pare, Boulogne
    Gastroenterol Clin Biol 30:2S24-2S29. 2006
  2. ncbi request reprint Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv
    P Rougier
    Hopital Ambroise Pare, Boulogne, France
    Lancet 351:1677-81. 1998
  3. ncbi request reprint [Colorectal cancer. A better screening, a better treatment]
    Philippe Rougier
    Hépato gastro entérologie, oncologie digestive, Hopital Ambroise Pare, 92104 Boulogne
    Rev Prat 54:133-4. 2004
  4. ncbi request reprint Epidemiology, treatment and chemoprevention in colorectal cancer
    P Rougier
    Hospital Ambroise Pare, Boulogne Billancourt, France
    Ann Oncol 14:ii3-5. 2003
  5. ncbi request reprint Review of the role of CPT-11 in the treatment of colorectal cancer
    P Rougier
    Department of Hepato Gastro Enterology and Digestive Oncology, Hospital Ambroise Pare, 92100 Boulogne, France
    Clin Colorectal Cancer 1:87-94. 2001
  6. ncbi request reprint Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study
    P Rougier
    Hopital Ambroise Pare, Boulogne, France
    Ann Oncol 13:1558-67. 2002
  7. ncbi request reprint The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer
    Véronique Veuillez
    Service Hépato Gastroentérologie et Oncologie Digestive, Hopital Ambroise Pare, AP HP, 92100 Boulogne, France
    Best Pract Res Clin Gastroenterol 21:947-63. 2007
  8. ncbi request reprint Second-line treatment of patients with metastatic colorectal cancer
    Philippe Rougier
    Hopital Ambroise Pare, 92100 Boulogne Billancourt, France
    Semin Oncol 32:S48-54. 2005
  9. ncbi request reprint Hepatocellular carcinoma (HCC): an update
    Philippe Rougier
    Service d Hepato Gastroenterologie, Hopital Ambroise Pare, 92100 Boulogne, France
    Semin Oncol 34:S12-20. 2007
  10. ncbi request reprint Chemotherapy in the treatment of neuroendocrine malignant tumors
    P Rougier
    Fédération des spécialités digestives, Service Hépato gastroentérologie, Hopital Ambroise Pare, Boulogne, France
    Digestion 62:73-8. 2000

Detail Information

Publications74

  1. ncbi request reprint Colon cancer
    Philippe Rougier
    Service d Hepato Gastroenterologie, Hopital Ambroise Pare, Boulogne
    Gastroenterol Clin Biol 30:2S24-2S29. 2006
  2. ncbi request reprint Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv
    P Rougier
    Hopital Ambroise Pare, Boulogne, France
    Lancet 351:1677-81. 1998
    ..We undertook a randomised controlled multicentre trial to investigate the efficacy of PVI (500 mg/m2 fluorouracil plus 5000 IU heparin daily for 7 days)...
  3. ncbi request reprint [Colorectal cancer. A better screening, a better treatment]
    Philippe Rougier
    Hépato gastro entérologie, oncologie digestive, Hopital Ambroise Pare, 92104 Boulogne
    Rev Prat 54:133-4. 2004
  4. ncbi request reprint Epidemiology, treatment and chemoprevention in colorectal cancer
    P Rougier
    Hospital Ambroise Pare, Boulogne Billancourt, France
    Ann Oncol 14:ii3-5. 2003
    ..Much CRC is familial, raising the prospect of targeted screening to aid early detection. Since the molecular events leading to CRC have become better characterized, there is also the possibility of developing chemoprotective agents...
  5. ncbi request reprint Review of the role of CPT-11 in the treatment of colorectal cancer
    P Rougier
    Department of Hepato Gastro Enterology and Digestive Oncology, Hospital Ambroise Pare, 92100 Boulogne, France
    Clin Colorectal Cancer 1:87-94. 2001
    ..CPT-11 was approved by the Food and Drug Administration in April 2000 for the first-line treatment of advanced CRC in combination with 5-FU/FA...
  6. ncbi request reprint Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study
    P Rougier
    Hopital Ambroise Pare, Boulogne, France
    Ann Oncol 13:1558-67. 2002
    ....
  7. ncbi request reprint The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer
    Véronique Veuillez
    Service Hépato Gastroentérologie et Oncologie Digestive, Hopital Ambroise Pare, AP HP, 92100 Boulogne, France
    Best Pract Res Clin Gastroenterol 21:947-63. 2007
    ....
  8. ncbi request reprint Second-line treatment of patients with metastatic colorectal cancer
    Philippe Rougier
    Hopital Ambroise Pare, 92100 Boulogne Billancourt, France
    Semin Oncol 32:S48-54. 2005
    ..Data from randomized phase III trials using a combination of chemotherapy and bevacizumab or cetuximab are necessary before incorporating these new agents into our routine practice...
  9. ncbi request reprint Hepatocellular carcinoma (HCC): an update
    Philippe Rougier
    Service d Hepato Gastroenterologie, Hopital Ambroise Pare, 92100 Boulogne, France
    Semin Oncol 34:S12-20. 2007
    ..Possible future therapeutic strategies include epidermal growth factor receptor inhibitors, antivascular endothelial growth factor therapies, cyclin D inhibitors, and HMG-CoA reductase inhibitors...
  10. ncbi request reprint Chemotherapy in the treatment of neuroendocrine malignant tumors
    P Rougier
    Fédération des spécialités digestives, Service Hépato gastroentérologie, Hopital Ambroise Pare, Boulogne, France
    Digestion 62:73-8. 2000
    ..New active chemotherapy regimens have to be tested clearly in this orphan group of tumors which does not hold much interest to the pharmaceutical companies...
  11. ncbi request reprint [Colorectal cancer management]
    Philippe Rougier
    Hépato gastro entérologie, oncologie digestive, Hopital Ambroise Pare, 92104 Boulogne
    Rev Prat 54:177-83. 2004
    ..Because of the efficacy of the new chemotherapy regimens, the availability of biotherapies and the fact that surgery can potentially cure more and more patients, colorectal cancer management needs to be multidisciplinary...
  12. ncbi request reprint Portal triad clamping (TC) or hepatic vascular exclusion (VE) for major liver resection after prolonged neoadjuvant chemotherapy? A case-matched study in 60 patients
    Stephane Benoist
    Department of Surgery, Hopital Ambroise Pare, Boulogne, France
    Surgery 140:396-403. 2006
    ..The aim of this case-matched study was to assess which method of vascular occlusion is most appropriate for major liver resection in patients who have undergone prolonged preoperative systemic chemotherapy...
  13. pmc Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Astrid Lievre
    Gastroenterology and Digestive Oncology Unit, Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne Billancourt, France
    BMC Cancer 9:347. 2009
    ..The aim of this study was to evaluate the activity of bevacizumab combined with FOLFIRI or FOLFOX in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin...
  14. doi request reprint Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases
    Antoine Brouquet
    Department of Surgery, AP HP, Hopital Ambroise Pare, Boulogne, France
    Surgery 145:362-71. 2009
    ..The aim of this study was to determine the risk factors for chemotherapy-associated liver injuries (CALI)...
  15. pmc Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
    Jean Luc Raoul
    Hopital Ambroise Pare, 9 avenue Charles de Gaulle, 92100 Boulogne Cedex, France
    BMC Cancer 9:112. 2009
    ....
  16. ncbi request reprint Cetuximab efficacy in patients treated routinely in university hospitals
    Jean Baptiste Bachet
    Hopital Ambroise Pare, APHP, Boulogne, Universite de Versailles Saint Quentin en Yvelines, UFR Paris Ile de France Ouest
    Gastroenterol Clin Biol 31:941-9. 2007
    ..The aim of this study was to evaluate the efficacy and tolerance of cetuximab (Cx) in patients with irinotecan-refractory metastatic colorectal cancer (IRMCRC) treated routinely at five university hospitals...
  17. ncbi request reprint [Conservative treatment undifferentiated neuroendocrine tumors of the anal canal: two cases]
    Celine Lepere
    Service d hépato gastroentérologie et d oncologie digestive, Fédération des spécialités digestives, Hopital Ambroise Pare, Boulogne Billancourt, France
    Gastroenterol Clin Biol 31:445-7. 2007
    ..We report two cases of poorly differentiated neuroendocrine tumors localized in the anal canal and treated by chemotherapy and radiotherapy resulting in prolonged complete local remission and preventing extended surgical excision...
  18. doi request reprint Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease
    Nicolas Mansencal
    Department of Cardiology, centre de référence pour les maladies cardiaques heréditaires, Boulogne, France
    Am J Cardiol 105:527-31. 2010
    ..2, 95% confidence interval 1.95 to 19.7, p = 0.002). In conclusion, TDI used during routine transthoracic echocardiography can be helpful to identify high-risk patients with CHD...
  19. doi request reprint Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials
    Emmanuel Mitry
    Hépato gastroentérologie et oncologie digestive, Hopital Ambroise Pare, Boulogne, France
    J Clin Oncol 26:4906-11. 2008
    ..We report here a pooled analysis based on individual data from these two trials...
  20. ncbi request reprint Complete response of colorectal liver metastases after chemotherapy: does it mean cure?
    Stephane Benoist
    Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne, France
    J Clin Oncol 24:3939-45. 2006
    ..Most patients with colorectal liver metastases (LMs) receive systemic chemotherapy. This study aimed to determine the significance of a complete response on imaging of LMs after chemotherapy...
  21. ncbi request reprint Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial
    Bernard Nordlinger
    Hospital Ambroise Pare, Assistance Publique Hopitaux de Paris, 9 avenue Charles de Gaulle, Boulogne Billancourt Cedex 92104, France
    Lancet Oncol 6:459-68. 2005
    ..The study also compared systemic chemotherapy with fluorouracil and folinic acid with that of fluorouracil and levamisole...
  22. ncbi request reprint Prognostic factor of recurrence for resected digestive endocrine tumors
    Mehdi Ouaissi
    Service de Chirurgie Generale et Digestive, Hopital Ambroise Pare, Paris, France
    Hepatogastroenterology 56:1183-9. 2009
    ..The aim of the present study was to identify the factors of recurrence for digestive endocrine tumours resected with curative intent...
  23. doi request reprint Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases
    Raymond Karkouche
    EA4340, Versailles University, APHP, Boulogne, France
    Eur J Gastroenterol Hepatol 24:1430-7. 2012
    ..Neuroendocrine carcinomas (NECs) are rare neoplasms with an increasing incidence. Oncogenetic pathways of colorectal NEC are still poorly understood, and no treatment standards are available for these rare tumors...
  24. doi request reprint The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer
    Frederique Peschaud
    Department of Surgery, Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne, Boulogne, France
    Ann Surg 248:1067-73. 2008
    ..The aim of the study was to evaluate the prognostic value of the ratio of metastatic to examined lymph nodes (LNR) in patients with rectal cancer...
  25. doi request reprint Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases
    Benjamin Angliviel
    Department of Surgery, AP HP, Hopital Ambroise Pare, Boulogne, France
    Ann Surg Oncol 16:1247-53. 2009
    ..The aim of this study was to determine the effect of chemotherapy on the accuracy of CT scan for the preoperative evaluation of colorectal liver metastases (LM)...
  26. doi request reprint Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment
    Emmanuel Mitry
    Hépatogastroentérologie et oncologie digestive, Hopital Ambroise Pare, 9 avenue Charles de Gaulle, 92100, Boulogne, France
    Int J Colorectal Dis 24:605-12. 2009
    ....
  27. doi request reprint Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome
    Christophe Tresallet
    AP HP, Fédération des spécialités digestives, Hopital Ambroise Pare, Université Versailles Saint Quentin en Yvelines, Boulogne, France
    Int J Cancer 130:1367-77. 2012
    ..Thus, like the revised Bethesda guidelines, predictive models did not identify all patients with Lynch syndrome in our series of consecutive CRC. Our results support systematic screening for MMR deficiency in all new CRC cases...
  28. doi request reprint Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy
    Aziz Zaanan
    Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, AP HP, Paris, France
    Clin Cancer Res 17:7470-8. 2011
    ..The aim of this study was to evaluate the prognostic value of MMR status for DFS in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy...
  29. doi request reprint Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
    Emmanuel Mitry
    Hépato gastroentérologie et oncologie digestive, Assistance Publique des Hopitaux de Paris, Hopital Ambroise Pare, 92104, Boulogne Billancourt, France
    Cancer Chemother Pharmacol 66:395-403. 2010
    ..To evaluate the efficacy and safety of masitinib combined with gemcitabine in patients with advanced pancreatic cancer...
  30. doi request reprint The timing of chemotherapy and surgery for the treatment of colorectal liver metastases
    Bernard Nordlinger
    Hopital Ambroise Pare, CHU Paris Ouest, Boulogne, France
    Clin Colorectal Cancer 9:212-8. 2010
    ....
  31. pmc Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
    Bernard Nordlinger
    centre hospitalier universitaire Ambroise Paré, Assistance Publique Hopitaux de Paris, Departments of Surgery and Oncology, Boulogne Billancourt, France
    Lancet 371:1007-16. 2008
    ..We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer...
  32. doi request reprint Echocardiographic follow-up of treated patients with carcinoid syndrome
    Nicolas Mansencal
    Department of Cardiology, Universite de Versailles Saint Quentin, Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne, France
    Am J Cardiol 105:1588-91. 2010
    ..Carcinoid heart disease progresses over time, highlighting the need for echocardiographic follow-up once carcinoid syndrome has been diagnosed...
  33. pmc Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases
    Mehdi Karoui
    Departments of Surgery, Hopital Ambroise Pare, Boulogne, France
    Ann Surg 243:1-7. 2006
    ..To assess the effects of preoperative systemic chemotherapy on remnant liver parenchyma, liver function, and morbidity after major liver resection for colorectal liver metastases...
  34. ncbi request reprint Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?
    Jean Baptiste Bachet
    Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne Billancourt, UVSQ Association ADEBIOPHARM ER48, Paris
    Gastroenterol Clin Biol 31:151-6. 2007
    ..Chemotherapy has been shown to be effective in the treatment of metastatic disease and we therefore evaluated its use as a first-line treatment for LAPC...
  35. doi request reprint Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases
    Gilles Manceau
    Department of Digestive Surgery and Surgical Oncology Ambroise Paré Hospital, APHP, Boulogne Billancourt, France
    Surgery 154:528-35. 2013
    ..The response of LM to radiochemotherapy has never been evaluated and, in particular, the risk for progression of LM is unknown...
  36. ncbi request reprint Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
    Bernard Nordlinger
    Hopital Ambroise Pare, CHU Paris Ouest, 92100 Boulogne Cedex, France
    Eur J Cancer 43:2037-45. 2007
    ....
  37. doi request reprint Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease
    Nicolas Mansencal
    Department of Cardiology, Universite de Versailles Saint Quentin, University Hospital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne, France
    Am J Cardiol 101:1035-8. 2008
    ..In conclusion, this prospective study demonstrates that in patients with CHD, the prevalence of PFO is high and that percutaneous closure of PFO is feasible, with a reduction in symptoms but with residual shunting...
  38. doi request reprint Cutaneous perianal recurrence on the site of Lone Star Retractor after J-pouch coloanal anastomosis for rectal cancer: report of two cases
    Hadrien Tranchart
    Department of Surgery, AP HP, Hopital Ambroise Pare, Boulogne, France
    Dis Colon Rectum 51:1850-2. 2008
    ..In two cases, recurrence occurred on the scars induced by elastic stay hook of Lone Star retractor. Both cases were treated by local excision alone. At one year of follow-up, there were no signs of local recurrence...
  39. pmc Autoimmune pancreatitis with atypical imaging findings that mimicked an endocrine tumor
    Cindy Neuzillet
    Department of Gastroenterology and Digestive Oncology, Ambroise Pare Hospital, 9, avenue Charles de Gaulle, 92100 Boulogne Billancourt, France
    World J Gastroenterol 16:2954-8. 2010
    ..The diagnosis was obtained by a pancreatic biopsy, thus avoiding surgical resection, and all the clinical, biological and radiological abnormalities resolved after steroid therapy with 6 mo of follow-up...
  40. ncbi request reprint Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma
    Jean Claude Barbare
    Service d Hepato Gastroenterologie, Centre Hospitalier, 8 avenue Henri Adnot, 60321 Compiègne, France
    J Clin Oncol 23:4338-46. 2005
    ..The aim of this study was to assess the efficacy of tamoxifen administration in improving overall survival of patients with advanced HCC...
  41. ncbi request reprint Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide
    Philippe Ruszniewski
    Hopital Beaujon, Clichy, France
    Neuroendocrinology 80:244-51. 2004
    ..Treatment was well tolerated. 28-day PR lanreotide was effective in reducing the symptoms and biochemical markers associated with carcinoid syndrome...
  42. ncbi request reprint [Treatment strategy for pancreatic endocrine tumours]
    Emmanuel Mitry
    Fédération des spécialités digestives, CHU Ambroise Pare, 9, avenue Charles de Gaulle, 92100 Boulogne
    Gastroenterol Clin Biol 27:S31-6. 2003
  43. ncbi request reprint Assessment of patent foramen ovale in carcinoid heart disease
    Nicolas Mansencal
    Department of Cardiology, University Hospital Ambroise Pare, Assistance Publique Hopitaux de Paris AP HP, Boulogne, France
    Am Heart J 151:1129.e1-6. 2006
    ..We attempted to evaluate the prevalence of CHD and patent foramen ovale (PFO) with serial contrast transthoracic echocardiographic studies and to determine the markers of right and left CHD progression...
  44. ncbi request reprint Metastatic colorectal cancer: first- and second-line treatment in 2005
    Philippe Rougier
    Hopital Ambroise Pare, Boulogne Billancourt, France
    Semin Oncol 32:15-20. 2005
    ..The type of adjuvant treatment, genomic consideration, and genetic predisposition will be determining factors in the ideal protocol for first-line therapy...
  45. ncbi request reprint Pancreatic metastases: a multicentric study of 22 patients
    Abdallah Moussa
    Service d hépato gastroentérologie et d oncologie digestive, Hopital Ambroise Pare, Boulogne Billancourt
    Gastroenterol Clin Biol 28:872-6. 2004
    ..To evaluate the diagnosis, treatment and outcome of patients with pancreatic metastases...
  46. doi request reprint Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening
    Catherine Julie
    Service d Anatomie et de Cytologie Pathologiques, Hopital Ambroise Pare, AP HP, Université Versailles Saint Quentin en Yvelines, Boulogne, France
    Am J Gastroenterol 103:2825-35; quiz 2836. 2008
    ..These criteria have been revised, and a new set of recommendations, the revised Bethesda guidelines, has been proposed...
  47. ncbi request reprint [PET and digestive cancers]
    Jean Noel Talbot
    Service de Medecine Nucleaire, AP HP, Hopital Tenon, F 75020 Paris, France
    Presse Med 37:e1-e24. 2008
    ....
  48. ncbi request reprint Nonsurgical methods for liver metastases including cryotherapy, radiofrequency ablation, and infusional treatment: what's new in 2001?
    Bernard Nordlinger
    Department of Surgery and Department of Gastroenterology and Oncology, Hopital Ambroise Pare, Boulogne, France
    Curr Opin Oncol 14:420-3. 2002
    ..Effective systemic chemotherapy regimens have resulted in increased survival rates and improved quality of life and in some cases have allowed resection of initially unresectable liver metastases...
  49. ncbi request reprint KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Astrid Lievre
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale UMR 775, Paris, France
    Cancer Res 66:3992-5. 2006
    ..The EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment...
  50. ncbi request reprint Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients
    Laetitia Dahan
    Service d Hepatogastroenterologie, unité d oncologie digestive, CHU Timone, Marseille, France
    Gastroenterol Clin Biol 29:11-5. 2005
    ..The aim of this retrospective and multicentric study was to determine the tolerance of a postoperative chemoradiotherapy regimen using LV5FU2 instead of the Mayo Clinic regimen...
  51. ncbi request reprint [What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]
    Jean Louis Legoux
    Services d Hépato gastroentérologie, Hopital Haut Leveque, CHU de Bordeaux, Pessac
    Gastroenterol Clin Biol 30:1191-5. 2006
  52. ncbi request reprint [Chemotherapy with curative intent before (neoadjuvant) or after (adjuvant) surgery for colorectal cancer liver metastases]
    Philippe Rougier
    Fédération des spécialités digestives, Hôpital Ambroise Paré 92100 Boulogne
    Bull Acad Natl Med 187:881-92. 2003
    ..If metastases resection has been facilitated or made possible by pre-operative chemotherapy, post-operative resumption of this chemotherapy should also been discussed (professional agreement)...
  53. ncbi request reprint [Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]
    Thierry Conroy
    Centre Alexis Vautrin, Nancy
    Bull Cancer 91:759-68. 2004
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  54. ncbi request reprint Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
    Olivier Bouche
    Centre Hospitalier Universitaire de Reims, RIMS, France
    J Clin Oncol 22:4319-28. 2004
    ....
  55. ncbi request reprint Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model
    Radan Dzodic
    Pharmacology Unit, Chatenay Malabry, France Institut Pasteur, Paris, France
    Anticancer Drugs 15:647-50. 2004
    ..v. administration with cisplatin. We conclude that there is a significant pharmacokinetic advantage to using oxaliplatin for locoregional IAH chemotherapy compared with i.v. administration...
  56. ncbi request reprint Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)
    Jacqueline Duffour
    CRLC Val d Aurelle Paul Lamarque, 34298 Montpellier, France
    Anticancer Res 26:3877-83. 2006
    ..FP (5-FU combined with Cisplatin) as a first line chemotherapy in advanced oesophageal, gastric and pancreatic cancer...
  57. ncbi request reprint [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]
    Julien Taieb
    Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Gastroenterol Clin Biol 26:605-9. 2002
    ..To prospectively evaluate efficacy and tolerance of the 5-fluorouracil + folinic acid + cisplatin (LV5FU2-P) combination in the treatment of unresectable pancreatic carcinoma...
  58. ncbi request reprint Liver metastases from colorectal cancer: the turning point
    Bernard Nordlinger
    J Clin Oncol 20:1442-5. 2002
  59. ncbi request reprint OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer
    Graeme J Poston
    Department of Surgery, Royal Liverpool University Hospital, Liverpool L7 8XP, UK
    J Clin Oncol 23:7125-34. 2005
    ..Since treatment strategy is frequently dependent on the response to earlier treatments, our aim was to create a therapeutic decision model identifying appropriate procedure sequences...
  60. ncbi request reprint [Recommendations for the management of GIST patients]
    Jean Yves Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon
    Bull Cancer 92:907-18. 2005
    ..A national consensus meeting was therefore organized in order to identify the optimal management procedures for patients with GIST in localized and advanced stages...
  61. ncbi request reprint Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial
    Guillaume Portier
    Chirurgie Digestive, CHU Purpan, Place du Dr Baylac, 31059 Toulouse, France
    J Clin Oncol 24:4976-82. 2006
    ..In order to decrease recurrences, the use of adjuvant systemic chemotherapy after liver resection is controversial because no randomized study demonstrated its benefit...
  62. ncbi request reprint Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note
    Anton J Bilchik
    John Wayne Cancer Institute at St John s Health Center, Santa Monica, CA, USA
    J Clin Oncol 23:9073-8. 2005
  63. ncbi request reprint Risk of venous thrombosis in patients with pancreatic adenocarcinoma
    Emmanuel Mitry
    Service d hépatogastroentérologie et oncologie digestive Hôpital Ambroise Paré, APHP Boulogne
    Gastroenterol Clin Biol 31:1139-42. 2007
    ..To estimate the risk of venous thrombosis associated with pancreatic adenocarcinoma and its consequences on treatment and survival...
  64. ncbi request reprint Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology
    Franck Bonnetain
    INSERM EMI 106 and Federation Francophone de Cancerologie Digestive, Faculty of Medicine, 7 bd Jeanne d Arc, BP 879000, 21079 Dijon Cedex
    Gastroenterol Clin Biol 29:1113-24. 2005
    ..The aim of this study was to compare the longitudinal quality of life (QoL) between LV5FU2-irinotecan and LV5FU2 alone or LV5FU2-cisplatin in a randomized Phase II trial in patients with metastatic gastric adenocarcinoma...
  65. ncbi request reprint Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial
    Emmanuel Mitry
    CHU Ambroise Pare, Boulogne
    Gastroenterol Clin Biol 30:357-63. 2006
    ..The efficacy and benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma has never been demonstrated although it is regularly used...
  66. doi request reprint Chemotherapy in elderly patients with colorectal cancer
    Claus Henning Köhne
    Klinik für Onkologie Hämatologie, Klinikum Oldenburg, Dr Eden Str 10, 26133 Oldenburg, Germany
    Oncologist 13:390-402. 2008
    ..The management of frail elderly patients and those with a short life expectancy should be focused on palliation, while fit elderly patients can receive aggressive therapy in a similar fashion to younger patients...
  67. doi request reprint KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
    Astrid Lievre
    L Institut National de la Santé et de la Recherche Médicale U775, Universite Paris Descartes, 45 Rue des Saints Peres, 75006 Paris, France
    J Clin Oncol 26:374-9. 2008
    ..The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival...
  68. doi request reprint Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    Gunnar Folprecht
    University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
    J Clin Oncol 26:1443-51. 2008
    ..Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)...
  69. doi request reprint Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab
    Ghassan El Maalouf
    J Neurol 255:295-6. 2008
  70. ncbi request reprint Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, Belgium
    Eur J Cancer 42:2212-21. 2006
    ....
  71. ncbi request reprint Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer
    Eugeniu Banu
    Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
    Drugs Aging 24:865-79. 2007
    ..To evaluate the impact on overall survival at 6, 12 and 18 months of gemcitabine-based doublets compared with gemcitabine alone in patients with advanced and metastatic pancreatic cancer...
  72. ncbi request reprint [The role of PET scan in gastrointestinal stromal tumors]
    Jean Louis Alberini
    Service de Médecine Nucléaire Centre René Huguenin CRLCC, 35 rue Dailly, 92210 Saint Cloud
    Gastroenterol Clin Biol 31:585-93. 2007
    ..PET may be proposed for the assessment of treatment response in prospective studies with imatinib or other molecules. In patients with GIST, FDG-PET should be performed based on a pluridisciplinary decision...
  73. ncbi request reprint [Ovarian adenocarcinoma, primary or metastasic tumour of an adenocarcinoma of the colon: the role of molecular biology]
    Nicolas Goasguen
    Laboratoire de Toxicologie Moléculaire, 45, rue des Saints Pères, 75006 Paris
    Gastroenterol Clin Biol 28:1165-7. 2004
    ..The comparative analysis suggested the primitive origin of the ovarian lesion...
  74. doi request reprint Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials
    Franck Bonnetain
    Methodological and Biostatistical unit, Fédération Francophone de Cancérologie Digestive, INSERM U866, Dijon, France
    Qual Life Res 17:831-43. 2008
    ....